This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
What’s your loop and thiazide of choice? Do you know which diuretics are better, faster, stronger? This week’s TenTweets is a two-fer (Chlorthalidone vs HCTZ and Furosemide vs Torsemide). Tweetorial catch-up here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) February 10, 2023
✳️10 tweets #NephJC catch-up ✳️
We all have our “go to” diuretics that are better, faster, stronger…but are they?
What evidence is there that one diuretic (in a class) is superior to another for CV outcomes?
It’s a 2-fer TenTweets.
Let’s go… pic.twitter.com/9Ms3zg8Z5z
Does Torsemide lower all cause mortality compared to furosemide for heart failure patients post-hospitalization? Cristina Popa elaborates, visually!
